ANI Pharmaceuticals, Inc.
$1.5M 21,104 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Seres Therapeutics, Inc.
Seres Therapeutics, Inc. reported $1,457,585.09 across General Payments, Research, and Ownership to 42 physicians and teaching hospitals across 198 transactions.
- $1.5M Above-median payer
- All-tracks total
- 198 Above-median volume
- Transactions
- 42 Below-median reach
- Recipients
- +$114.4K
- General Payments vs PY2023
Seres Therapeutics, Inc. reported $1,457,585.09 across all CMS Open Payments tracks (General + Research + Ownership) to 42 physicians and teaching hospitals in Program Year 2024 - ranking #532 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $132,447.88, averaging $34.7K per recipient.
How Seres Therapeutics, Inc.'s $1.5M all-tracks total breaks down
Seres Therapeutics, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
20/100
Total payments
F
23/100
Transaction volume
F
11/100
Physician reach
F
10/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer seres-therapeutics-inc Seres Therapeutics, Inc.
$1.5M · #532/1,925 · 0.0% industry · PY2024
- TOT $1.5M
- RANK #532
- SHARE 0.0%
- TXN 198
- RCP 42
- CAT 3
- GEN $132.4K
- ΔGEN +$114.4K
- TOP1 43.7%
- PY 2024
Volume peers
Nearest volume peer: ANI Pharmaceuticals, Inc. ($1.5M)
Seres Therapeutics, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Seres Therapeutics, Inc.'s CMS-reported General Payments increased by $114.4K (+633.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2023: SERES THERAPEUTICS, INC.PY2024: Seres Therapeutics, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $18,048.36
- PY2024
- $132,447.88
What the Data Shows for Seres Therapeutics, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Seres Therapeutics, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Consulting Fee" leads the 3-category general-payment breakdown below at $121.1K (91.4% of General Payments, 18 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 3 types of general payments, Seres Therapeutics, Inc.'s largest category was "Consulting Fee" at $121.1K - 91.4% of General Payments.
How Seres Therapeutics, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $121.1K | 18 | 91.4% |
| Travel and Lodging | $10.9K | 17 | 8.2% |
| Food and Beverage | $476.59 | 7 | 0.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $131,400.55 (99.2%) of $132,447.88 in this company's General Payments records across 12 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Seres Therapeutics, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Willard Dere
$57,820.55 across 21 reported transactions
- 2
Dennis Ausiello
$37,500.00 across 3 reported transactions
- 3
Timothy Leach
$34,200.00 across 8 reported transactions
- 4
Elizabeth Ghera
$1,080.00 across 1 reported transactions
- 5
Randy Taplitz
$800.00 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Seres Therapeutics, Inc.'s spend rank (#532 of 1,925, top 28% by spend) and concentration rank (#520 of 1,838, top 28% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Granata Bio Corporation : $5.5K total payments, HHI 3437
- American Rheumatology Network, LLC : $2.8M total payments, HHI 3431
- Biocircuit Technologies Inc : $69.8K total payments, HHI 3424
- Organ Recovery Systems, Inc. : $356.7K total payments, HHI 3422
- Omniscient Neurotechnology America Ltd : $73.2K total payments, HHI 3397
- FlexDex Inc. : $350.51 total payments, HHI 3376
- Seres Therapeutics, Inc. (this company) : $132.4K total payments, HHI 3375
- Orthopedic Sciences, Inc. : $4.0K total payments, HHI 3369
- L&k Biomed Co. , Ltd. : $864.8K total payments, HHI 3358
- Nidek Incorporated : $16.8K total payments, HHI 3356
- Grifols Diagnostic Solutions, Inc. : $48.20 total payments, HHI 3353
- Roche Diabetes Care GmbH : $52.4K total payments, HHI 3353
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Seres Therapeutics, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Seres Therapeutics, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Seres Therapeutics, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
FUJIFILM Healthcare Americas Corporation
$1.5M 993 recipients
Compare payment profiles
Rti Surgical, Inc
$1.4M 821 recipients
Compare payment profiles
Esteve Pharmaceuticals LLC
$1.4M 8 recipients
Compare payment profiles
Servier Pharmaceuticals LLC
$1.5M 5,634 recipients
Compare payment profiles
Adaptive Biotechnologies Corporation
$1.5M 3,663 recipients
Compare payment profiles
Put this to use
Seres Therapeutics, Inc. ranks #532 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Seres Therapeutics, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Seres Therapeutics, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.